Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech held its 38th AGM on September 30, 2025, via video conferencing from 3:00 PM to 3:35 PM. Three ordinary resolutions were passed with near-unanimous shareholder approval (~99.99% in favor). These included: (1) adoption of audited standalone and consolidated financial statements for FY ending March 31, 2025, (2) re-appointment of Dr. Sankaranarayanan Alangudi (DIN: 02703392) as director retiring by rotation, and (3) appointment of Mr. Vinay Babu Gade as Secretarial Auditor. Out of 21,333,221 total outstanding shares, 8,731,845 votes were polled (40.93% turnout). Promoters (7,771,500 shares) voted 100% in favor on all resolutions, while only around 1,110-1,120 public votes were cast against each resolution. The meeting saw 6 promoter group members and 70 public shareholders attend via VC out of 21,954 total shareholders on the record date of September 23, 2025.
This is a routine regulatory filing confirming smooth passage of standard AGM resolutions with overwhelming shareholder support. No material governance red flags or contentious issues were raised. Negligible impact on stock price expected as these are procedural matters.